Home › At 2014 San Antonio Breast Cancer Symposium three new Myriad studies highlighted
 

Keywords :   


At 2014 San Antonio Breast Cancer Symposium three new Myriad studies highlighted

2014-12-13 11:24:24| Biotech - Topix.net

Myriad Genetics, Inc. has announced results from a new study that demonstrated the ability of the myRisk Hereditary Cancer test to detect 105 percent more mutations in cancer causing genes than conventional BRCA testing alone. The Company also presented two key studies in triple negative breast cancer that show the myChoice HRD test accurately predicted response to platinum-based therapy in patients with early-stage TNBC and that the BRACAnalysis molecular diagnostic test significantly predicted response to platinum-based drugs in patients with metastatic TNBC.

Tags: san studies antonio cancer

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
10.05Senators request more aggressive approach on HPAI countermeasures
10.05Lidl raises pay to match Aldi in battle for staff
10.05Faisal Islam: Economy is getting better but people may not notice
10.05Sulfate-Free Foamable Solid Cleanser Patented by Johnson & Johnson
10.05Farm Progress America, May 10, 2024
10.05Farm Progress America, May 10, 2024
10.05Bank 'optimistic' as it edges closer to summer cut
10.05Comcast releases research on how viewers discover new TV content
More »